| pubmed-article:1664342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1664342 | lifeskim:mentions | umls-concept:C0030281 | lld:lifeskim |
| pubmed-article:1664342 | lifeskim:mentions | umls-concept:C0020456 | lld:lifeskim |
| pubmed-article:1664342 | lifeskim:mentions | umls-concept:C0022245 | lld:lifeskim |
| pubmed-article:1664342 | lifeskim:mentions | umls-concept:C1551336 | lld:lifeskim |
| pubmed-article:1664342 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:1664342 | pubmed:dateCreated | 1992-3-17 | lld:pubmed |
| pubmed-article:1664342 | pubmed:abstractText | During long-term increase in isoprenaline (pronounced beta-effect) and isoprenaline plus regitine (pure beta-effect) pancreatic insulin-secretion still depended mostly on blood glucose levels. This means that increased beta-effect during normo- or hypoglycemia could not cause a higher insulin-secretion. Only during additional alpha-receptor blockade insulin-secretion was slightly but insufficiently increased. Catecholamines seem to be more regulator than originator of the insulin secretory process. | lld:pubmed |
| pubmed-article:1664342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1664342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1664342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1664342 | pubmed:issn | 0232-1513 | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:SchwarzUU | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:WernerMM | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:PortaSS | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:RinnerII | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:KorsatkoWW | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:HimlyCC | lld:pubmed |
| pubmed-article:1664342 | pubmed:author | pubmed-author:PonczaBB | lld:pubmed |
| pubmed-article:1664342 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1664342 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:1664342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1664342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1664342 | pubmed:pagination | 57-61 | lld:pubmed |
| pubmed-article:1664342 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:meshHeading | pubmed-meshheading:1664342-... | lld:pubmed |
| pubmed-article:1664342 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1664342 | pubmed:articleTitle | Isoprenaline cannot act on pancreatic beta cells without hyperglycemia or alpha-block. | lld:pubmed |
| pubmed-article:1664342 | pubmed:affiliation | University of Graz, Institute of Functional Pathology, Austria. | lld:pubmed |
| pubmed-article:1664342 | pubmed:publicationType | Journal Article | lld:pubmed |
